Our data confirm the previously suggested hypothesis that the use of selective PPAR subtype ligands may represent an opportunity to develop new therapeutic strategies for traumatic brain injuries and neurodegenerative diseases [6]. This evidence concerns the gene PPARA and neurodegenerative disease.